Abstracts tagged "Biomarkers"

Abstract Number: 2584 • 2015 ACR/ARHP Annual Meeting
Prediction of Disease Relapses By Multi-Biomarker Disease Test Activity in Rheumatoid Arthritis Patients Tapering DMARD Treatment
Juergen Rech¹, Axel J. Hueber², Matthias Englbrecht², Stephanie Finzel³, Judith Haschka^4,5, Bernhard Manger², Arnd Kleyer³, Michaela Reiser³, Hans-Peter Tony⁶, Stefan Kleinert⁷, Martin Feuchtenberger⁸, Martin Fleck⁹, Karin Manger¹⁰, Wolfgang Ochs¹¹, Matthias Schmitt-Haendle¹², Joerg Wendler¹³, Florian Schuch¹³, Monika Ronneberger¹³, Hanns-Martin Lorenz¹⁴, Hubert Nüßlein¹⁵, Rieke Alten¹⁶, Jayme Fogagnolo Cobra¹⁷, Joerg C. Henes¹⁸, Klaus Krüger¹⁹ and Georg A. Schett²⁰, ¹medical clinic 3, University of Erlangen-Nuremberg, Erlangen, Germany, ²Department of Internal Medicine 3, Rheumatology & Immunology, University of Erlangen-Nuremberg, Erlangen, Germany, ³Department of Internal Medicine 3, University of Erlangen-Nuremberg, Erlangen, Germany, ⁴Medical Department 3, Rheumatology & Immunology, University of Erlangen-Nuremberg, Erlangen, Germany, ⁵Medical Department II, Medical University of Vienna, St. Vincent Hospital Vienna,, Vienna, Austria, ⁶University Hospital Würzburg, Würzburg, Germany, ⁷Rheumatologische Schwerpunktpraxis Erlangen, Erlangen, Germany, ⁸Rheumatologie/Klinische Immunologie, Kreiskliniken Altötting-Burghausen, Burghausen, Germany, ⁹Department of Internal Medicine I, University of Regensburg, 93042 Regensburg, Germany, ¹⁰Rheumatology Practice Bamberg, Bamberg, Germany, ¹¹Rheumatologist in Private Practice, Bayreuth, Germany, ¹²Rheumatology Practice, Bayreuth, Germany, ¹³Schwerpunktpraxis Rheumatologie, Erlangen, Germany, ¹⁴University Hospital Heidelberg, Heidelberg, Germany, ¹⁵University Erlangen, Nürnberg, Germany, ¹⁶Internal Medicine, Rheumatology & Clinical Immunology, Schlosspark-Klinik, University Medicine Berlin, Berlin, Germany, ¹⁷Instituto de Reumatologia de Sao Paolo, Sao Paolo, Brazil, ¹⁸Department of Internal Medicine II, Rheumatology Division, University Hospital Tuebingen, Tuebingen, Germany, ¹⁹Praxiszentrum St. Bonifatius, München, Germany, ²⁰University of Erlangen-Nuremberg, Erlangen, Germany
Background/Purpose: To analyze the role of multi-biomarker disease activity (MBDA) in predicting disease relapses in rheumatoid arthritis (RA) patients in sustained remission, tapering disease modifying…
Abstract Number: 2965 • 2015 ACR/ARHP Annual Meeting
Might Troponin be a Marker for Subclinical Scleroderma Heart Involvement (SHI)?
Chiara Stagnaro¹, Anna d'Ascanio¹, Alice Parma², Umberto Conti³, Michele Emdin⁴, Alessandra Della Rossa¹ and Marta Mosca¹, ¹Internal Medicine, University of Pisa, Pisa, Italy, ²University of Pisa, Pisa, Italy, ³Cardiotoracico, Cardiologia 2, Pisa, Italy, ⁴Fondazione Toscana Gabriele Monasterio, UOC Cardiologia e Medicina Cardiovascolare, Pisa, Italy
Background/Purpose: Systemic sclerosis (SSc) is a rare connective tissue disease with pronounced alterations of the microvascular system, frequent cellular and humoral immunity abnormalities and fibroblast…
Abstract Number: 2880 • 2014 ACR/ARHP Annual Meeting
Elevated Levels of Soluble Inflammatory Mediators and Lupus-Specific Connective Tissue Disease Questionnaire Scores Discern Unaffected First Degree Relatives of Lupus Patients from Unaffected Individuals Not Related to Lupus Patients
Melissa E. Munroe¹, Kendra A. Young², Jennifer Fessler³, Dustin Fife³, Diane L. Kamen⁴, Joel M. Guthridge³, Timothy B. Niewold⁵, Michael H. Weisman⁶, Mariko L. Ishimori⁶, Daniel J. Wallace⁷, David R. Karp⁸, John B. Harley⁹, Gary S. Gilkeson⁴, Jill M. Norris² and Judith A. James^10,11, ¹Arthritis and Clinical Immunology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, ²Epidemiology, Colorado School of Public Health, Aurora, CO, ³Arthritis and Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁴Department of Medicine, Division of Rheumatology, Medical University of South Carolina, Charleston, SC, ⁵Division of Rheumatology and Department of Immunology, Mayo Clinic, Rochester, MN, ⁶Rheumatology, Cedars-Sinai Medical Center, Los Angeles, CA, ⁷Division of Rheumatology, Cedars-Sinai Medical Center, Los Angeles, CA, ⁸Rheumatic Diseases Division, UT Southwestern Medical Center, Dallas, TX, ⁹Center for Autoimmune Genomics and Etiology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ¹⁰Clinical Arthritis and Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK, ¹¹Rheumatology, University of Oklahoma Health Sciences Center, Oklahoma City, OK
Background/Purpose: Identifying populations at risk of SLE is essential to curtail inflammatory damage and select individuals for prevention trials. First-degree relatives (FDRs) of lupus patients…
Abstract Number: 1897 • 2014 ACR/ARHP Annual Meeting
Circulating T-Helper Cell- Associated Cytokines and Chemokines in Localized Scleroderma
Kathryn S. Torok¹, Katherine Kurzinski², Christina Kelsey³, Kelsey Magee⁴, Jonathan Yabes⁵, Abbe N. Vallejo⁶, Thomas A. Medsger Jr.⁷ and Carol A. Feghali-Bostwick⁸, ¹Pediatric Rheumatology, Children's Hospital of Pittsburgh of UPMC, Pittsburgh, PA, ²Pediatric Rheumatology, Univ of Pittsburgh Med Ctr, Pittsburgh, PA, ³Pediatric Rheumatology, University of Pittsburgh/UPMC, Pittsburgh, PA, ⁴Pediatric Rheumatology, University of Pittsburgh, Pittsburgh, PA, ⁵Department of Medicine, University of Pittsburgh, Pittsburgh, PA, ⁶Department of Immunology, University of Pittsburgh, Pittsburgh, PA, ⁷Medicine/Rheumatology, University of Pittsburgh, Pittsburgh, PA, ⁸Medicine, Medical University of South Carolina, Charleston, SC
Background/Purpose: Localized scleroderma (LS) is an autoimmune disease of the skin and underlying tissues which results in disfigurement and orthopedic complications, especially when the onset…
Abstract Number: 1309 • 2014 ACR/ARHP Annual Meeting
Does Anti-C1q Antibody Have Diagnostic and Prognostic Roles in Childhood – Onset Systemic Lupus Erythematosus?
Thaschawee Arkachaisri¹, Joo Guan Yeo², Justin Hung Tiong Tan³, Sook Fun Hoh⁴, Lena Das³ and Jing Yao Leong², ¹Rheumatology & Immunology, KK Women's and Children's Hospital, Singapore, Singapore, ²Children Intensive Care Unit (CICU), KK Women's and Children's Hospital, Singapore, Singapore, ³Rheumatology and Immunology, KK Women's and Children's Hospital, Singapore, Singapore, ⁴Nursing, KK Women's and Children's Hospital, Singapore, Singapore
Background/Purpose: Biomarkers proven to be effective in aSLE patients may not directly apply to cSLE unless validation is done. Existing evidences have shown immunopathogenic roles…
Abstract Number: 760 • 2014 ACR/ARHP Annual Meeting
Use of Multiplex Cytokine Analysis of Dermal Blister Fluid to Assess Local Inflammatory and Immune Activity in Systemic Sclerosis
Kristina E.N. Clark¹, Henry Lopez², Xu Shiwen¹, Bahja Ahmed Abdi¹, George Martin³, Korsa Khan⁴, David J. Abraham¹, Christopher P. Denton⁵ and Richard J. Stratton¹, ¹Centre for Rheumatology and Connective Tissue Diseases, UCL Medical School, London, United Kingdom, ²Murigenics, Vallejo, CA, ³Aero Dap, Vallejo, CA, ⁴Centre for Rheumatology and Connective Tissue Diseases, UCL medical School, London, United Kingdom, ⁵Centre for Rheumatology and Connective Tissue Diseases, UCL Medical School Royal Free Campus, London, United Kingdom
Background/Purpose Clinical diversity in systemic sclerosis (SSc) suggests complex multifaceted pathogenesis involving interplay of growth factors or cytokines within the lesional microenvironment. We analysed dermal…
Abstract Number: 364 • 2014 ACR/ARHP Annual Meeting
In Early Rheumatoid Arthritis, the Multi-Biomarker Disease Activity Score at Different Time-Points Is Predictive of Subsequent Radiographic Progression
Karen Hambardzumyan¹, R.J. Bolce², Saedis Saevarsdottir*³, Kristina Forslind⁴, Ingemar F. Petersson⁵, Pierre Geborek⁶, Eric H. Sasso², David Chernoff², Scott Cruickshank⁷ and Ronald F. van Vollenhoven⁸, ¹ClinTRID, the Karolinska Institute, Stockholm, Sweden, ²Crescendo Bioscience Inc., South San Francisco, CA, ³Rheumatology Unit, Karolinska University Hospital, Karolinska Institutet, Stockholm, Sweden, ⁴Department of Medicine, Karolinska Institute, Stockholm, Sweden, ⁵Lund University, Lund, Sweden, ⁶Section of Rheumatology, Department of Clinical Sciences Lund, Lund University, Lund, Sweden, ⁷Scott Cruickshank and Associates, Inc., Santa Barbara, CA, ⁸Unit for clinical therapy research (ClinTrid), Karolinska Institute, Stockholm, Sweden
Background/Purpose The prediction of radiographic progression in early rheumatoid arthritis (eRA) patients is important for optimal treatment. We previously demonstrated that a multi-biomarker disease activity…
Abstract Number: 2795 • 2014 ACR/ARHP Annual Meeting
Blockade of IL-6R Signaling by Sarilumab Suppressed Circulating Markers of Bone Resorption and Synovial Damage in Rheumatoid Arthritis Patients from a Phase 3, Randomized, Double-Blind, Placebo-Controlled, International Study
Anita Boyapati¹, Jérôme Msihid², Emmanuelle Cousin³, Ling Cai⁴, Janet van Adelsberg¹, Jennifer D Hamilton¹, Neil Graham⁵, Tanya Momtahen⁶ and Stefano Fiore⁷, ¹Regeneron Pharmaceuticals, Inc., Tarrytown, NY, ²Sanofi R&D, France, Chilly-Mazarin, NJ, France, ³Sanofi R&D, France, Chilly-Mazarin, France, ⁴Sanofi R&D, China, Beijing, China, ⁵Program Direction, Regeneron Pharmaceuticals, Inc., Tarrytown, NY, ⁶Sanofi, Bridgewater, NJ, ⁷Distinct Project Unit, Sanofi, Bridgewater, NJ
Background/Purpose Rheumatoid arthritis (RA) patients develop bone and joint damage due to chronic inflammation mediated by critical cytokines, eg, IL-6. Pre-clinical studies have implicated IL-6…
Abstract Number: 1754 • 2014 ACR/ARHP Annual Meeting
Peripheral CD5⁺b-Cells in ANCA-Associated Vasculitis
Sebastian Unizony¹, Noha Lim², Vincent Carey³, Deborah J. Phippard², Nadia Tchao², Eli M. Miloslavsky⁴, Peter A. Merkel⁵, Paul Monach⁶, William St. Clair⁷, Robert F. Spiera⁸, Adam Asare², Philip Seo⁹, Carol A. Langford¹⁰, Gary S. Hoffman¹¹, Cees Kallenberg¹², Ulrich Specks¹³ and John H. Stone⁴, ¹Rheumatology, Allergy and Immunology, Massachusetts General Hospital, Boston, MA, ²Immune Tolerance Network, Bethesda, MD, ³Channing Division of Network Medicine, Brigham and Women's Hospital, Boston, MA, ⁴Rheumatology, Massachusetts General Hospital, Boston, MA, ⁵Vasculitis Center, Division of Rheumatology, University of Pennsylvania, Philadelphia, PA, ⁶Rheumatology, Boston University, Boston, MA, ⁷Rheumatology and Immunology, Duke University, Durham, NC, ⁸Rheumatology, Hospital for Special Surgery, New York, NY, ⁹Rheumatology Division, Johns Hopkins Vasculitis Center, Johns Hopkins University, Baltimore, MD, ¹⁰Center for Vasculitis Care and Research, Cleveland Clinic, Cleveland, OH, ¹¹Rheumatic & Immunologic Dis, Cleveland Clinic Foundation, Cleveland, OH, ¹²Rheumatology and Clinical Immunology, University of Groningen, Groningen, Netherlands, ¹³Frederichs Dr NW, Mayo Clinic, Rochester, MN
Background/Purpose We explored the utility of peripheral CD19+ CD5+ B-cells (CD5+ B-cells) as biomarkers in ANCA-associated vasculitis (AAV) Methods CD5+ B-cells were measured longitudinally by…
Abstract Number: 1308 • 2014 ACR/ARHP Annual Meeting
Antinucleosome Antibodies As Potential Diagnostic and Prognostic Biomarkers in Childhood Onset Systemic Lupus Erythematosus
Thaschawee Arkachaisri¹, Joo Guan Yeo², Justin Hung Tiong Tan³, Sook Fun Hoh⁴, Lena Das³ and Jing Yao Leong², ¹Rheumatology & Immunology, KK Women's and Children's Hospital, Singapore, Singapore, ²Children Intensive Care Unit (CICU), KK Women's and Children's Hospital, Singapore, Singapore, ³Rheumatology and Immunology, KK Women's and Children's Hospital, Singapore, Singapore, ⁴Nursing, KK Women's and Children's Hospital, Singapore, Singapore
Background/Purpose: The role of antinucleosome antibodies (ANuA) in the immunopathogenesis of SLE is evident. ANuA was shown to be a good, if not better than…
Abstract Number: 754 • 2014 ACR/ARHP Annual Meeting
The Global miRNA Whole Blood Profile in Systemic Sclerosis and Its Correlation with Serum Cytokine Levels
Gloria Salazar¹, Maureen Mayes², John Hagan³, Minghua Wu¹, John D. Reveille^4,5 and Shervin Assassi¹, ¹Rheumatology, University of Texas Health Science Center at Houston, Houston, TX, ²Internal Medicine/Rheumatology, University of TX Health Science Center -Houston, Houston, TX, ³Neurosurgery, University of Texas at Houston, Houston, TX, ⁴Internal Medicine/Rheumatology, University of Texas Health Science Center at Houston, Houston, TX, ⁵Internal Medicine/Rheumatology, Univ of Texas Health Science Center at Houston, Houston, TX
The Global miRNA Whole Blood Profile in Systemic Sclerosis and its Correlation with Serum Cytokine LevelsBackground/Purpose: Several studies have implicated miRNAs in the pathogenesis of…
Abstract Number: 376 • 2014 ACR/ARHP Annual Meeting
Using the Multi-Biomarker Disease Activity Score As a Complementary Inclusion Criterion for Clinical Trials in Rheumatoid Arthritis May Enhance Recruitment
Ronald F. van Vollenhoven¹, Rebecca J. Bolce², Karen Hambardzumyan³, Saedis Saevarsdottir⁴, Kristina Forslind⁴, Ingemar Petersson⁵, Eric H. Sasso², CC Hwang⁶, Oscar Segurado² and Pierre Geborek⁷, ¹Unit for clinical therapy research (ClinTrid), Karolinska Institute, Stockholm, Sweden, ²Crescendo Bioscience Inc., South San Francisco, CA, ³ClinTRID, the Karolinska Institute, Stockholm, Sweden, ⁴Department of Medicine, Karolinska Institute, Stockholm, Sweden, ⁵Lund University, Department of Orthopedics, Clinical Sciences Lund, Lund, Sweden, ⁶Biostatistics, Crescendo Bioscience Inc., South San Francisco, CA, ⁷Section of Rheumatology, Department of Clinical Sciences Lund, Lund University, Lund, Sweden
Background/Purpose Clinical trials in rheumatoid arthritis (RA) often require elevated C-reactive protein (CRP) as an inclusion criterion, which may limit recruitment by excluding some patients…
Abstract Number: 2787 • 2014 ACR/ARHP Annual Meeting
Identification of Urinary Biomarkers for Lupus Nephritis
Carolina Landolt-Marticorena¹, Stephenie Prokopec², Heather Reich³, James Scholey⁴, Carmen Avila-Casado⁵, Paul R. Fortin⁶, Paul Boutros² and Joan Wither⁷, ¹Rheumatology, Toronto Western Hospital, Toronto, ON, Canada, ²Ontario Institute for Cancer Research, Toronto, ON, Canada, ³Nephrology, University Health Network, Toronto, ON, Canada, ⁴Department of Medicine, The Toronto Western Hospital, Toronto, ON, Canada, ⁵Pathology, University Health Network, Toronto, ON, Canada, ⁶Rheumatology, Laval University, Division of Rheumatology, Centre de Recherche du CHU de Québec and Department of Medicine, Quebec City, QC, Canada, ⁷Immunology, University of Toronto, Toronto, ON, Canada
Background/Purpose: Lupus nephritis (LN) is a major determinant of morbidity and mortality in Systemic Lupus Erythematosus (SLE). Variability in clinical course, underlying renal injury, and…
Abstract Number: 1730 • 2014 ACR/ARHP Annual Meeting
Identification of Novel Scleroderma –associated Antigens and Development of an Autoantibody Assay Panel Enabling Their Subsequent Validation
Hans-Dieter Zucht¹, Petra Budde¹, Peter Schulz-Knappe¹, Nicolas Hunzelmann², Karsten Conrad³ and Prof. Dr. Matthias Schneider⁴, ¹Protagen AG, Dortmund, Germany, ²Department of Dermatology, University of Cologne, Cologne, Germany, ³Medizinische Fakultät Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany, ⁴Department of Rheumatology, Univ. Duesseldorf, Duesseldorf, Germany
Background/Purpose: Scleroderma (systemic sclerosis or SSc) has a highly variable clinical presentation and course resulting in difficulties for disease management. When SSc is suspected, autoantibodies…
Abstract Number: 1293 • 2014 ACR/ARHP Annual Meeting
Identification of an Inflammation-Driven Phenotype of Osteoarthritis By Quantification of Synovial Inflammation Ex Vivo and in Serum from Patients
Cecilie F. Kjelgaard-Petersen¹, Anne Sofie Siebuhr², Kristian Kjaer Petersen³, Lars Arendt-Nielsen⁴, Thomas Eskehave⁵, Hans Christian Hoeck⁵, Ole Simonsen⁶, Thorbjørn Christiansen⁷, Line Lindhardt Egsgaard⁸, Morten A. Karsdal⁹ and Anne C. Bay-Jensen¹, ¹Nordic Bioscience, Biomarkers and Research, Herlev, Denmark, ²Rheumatology, Nordic Bioscience, Biomarkers and Research, Herlev, Denmark, ³Department of Health Science and Technology, Faculty of Medicine, Aalborg University, Denmark, Center for Sensory-Motor Interaction, Aalborg, Denmark, ⁴Department of Health Science and Technology, Faculty of Medicine, Aalborg University, Center for Sensory-Motor Interaction, Aalborg, Denmark, ⁵Center for Clinical and Basic Research (CCBR), Aalborg, Denmark, ⁶Frederikshavn Hospital, Frederikshavn, Denmark, ⁷Orthopaedic Surgery Unit, Gentofte University Hospital, Gentofte, Denmark, ⁸Center for Sensory-Motor Interaction (SMI), Aalborg University, Aalborg, Denmark, ⁹Research & Development, Nordic Bioscience, Biomarkers and Research, Herlev, Denmark
Background/Purpose Osteoarthritis (OA) is a multifaceted degenerative joint disease, where inflammation of the synovial membrane leads to accelerated joint destruction, resulting in elevated release of…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].